Supporting information

Similar documents
p-toluenesulfonic Acid-Mediated 1,3-Dipolar Cycloaddition of

Supporting Information. Copyright Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, 2007

Masatoshi Shibuya,Takahisa Sato, Masaki Tomizawa, and Yoshiharu Iwabuchi* Department of Organic Chemistry, Graduate School of Pharmaceutical Sciences,

Manganese powder promoted highly efficient and selective synthesis of fullerene mono- and biscycloadducts at room temperature

SUPPORTING INFORMATION

Rameshwar Prasad Pandit and Yong Rok Lee * School of Chemical Engineering, Yeungnam University, Gyeongsan , Korea

Copyright Wiley-VCH Verlag GmbH, D Weinheim, Angew. Chem

Regioective Halogenation of 2-Substituted-1,2,3-Triazole via sp 2 C-H Activation

Lewis acid-catalyzed regioselective synthesis of chiral α-fluoroalkyl amines via asymmetric addition of silyl dienolates to fluorinated sulfinylimines

Preparation of Stable Aziridinium Ions and Their Ring Openings

Stereoselective Aza-Darzens Reactions of Tert- Butanesulfinimines: Convenient Access to Chiral Aziridines

Supporting Information

Enantioselective synthesis of anti- and syn-β-hydroxy-α-phenyl carboxylates via boron-mediated asymmetric aldol reaction

Synthesis and Blastocyst Implantation Inhibition Potential of Lupeol Derivatives in Female Mice

Chiral Squaramide Derivatives are Excellent Hydrogen Bond Donor Catalysts. Jeremiah P. Malerich, Koji Hagihara, and Viresh H.

Supporting Information

Supporting Information

Supporting Information. An Efficient Synthesis of Optically Active Physostigmine from Tryptophan via Alkylative Cyclization

Divergent Construction of Pyrazoles via Michael Addition of N-Aryl Hydrazones to 1,2-Diaza-1,3-dienes

Supporting Information Synthesis of 2-Aminobenzonitriles through Nitrosation Reaction and Sequential Iron(III)-Catalyzed C C Bond Cleavage of 2-Arylin

Zinc Chloride Promoted Formal Oxidative Coupling of Aromatic Aldehydes and Isocyanides to α- Ketoamides

Electronic Supplementary Information

Supporting Materials. Experimental Section. internal standard TMS (0 ppm). The peak patterns are indicated as follows: s, singlet; d,

yellow coloured amorphous powder, which on crystallization from hot acetone resulted in pale

Supporting Information. Efficient copper-catalyzed Michael addition of acrylic derivatives with primary alcohols in the presence of base

Asymmetric organocatalytic diboration of alkenes

Supporting Information for. Use of the Curtius Rearrangement of Acryloyl Azides in the Synthesis of. 3,5-Disubstituted Pyridines: Mechanistic Studies

Ethyl 2-hydroxy-4-methyl-1-((prop-2-yn-1-yloxy)methyl)cyclohex-3-enecarboxylate (16):

Catalytic decarboxylative alkylation of β-keto acids with sulfonamides via the cleavage of carbon nitrogen and carbon carbon bonds

ph Switchable and Fluorescent Ratiometric Squarylium Indocyanine Dyes as Extremely Alkaline Sensors

Cu-Catalyzed Direct C6-Arylation of Indoles

Electronic Supplementary Information. Quinine/Selectfluor Combination Induced Asymmetric Semipinacol Rearrangement of

Preparation of Fluorinated Tetrahydropyrans and Piperidines using a New Nucleophilic Fluorination Reagent DMPU/HF

Thiol-Activated gem-dithiols: A New Class of Controllable. Hydrogen Sulfide (H 2 S) Donors

Supporting Information. Palladium-Catalyzed Formylation of Aryl Iodides with HCOOH as

Supporting Information

Pyridazine N-Oxides as Precursors of Metallocarbenes: Rhodium-Catalyzed Transannulation with Pyrroles. Supporting Information

Supporting Information. Copper-catalyzed cascade synthesis of benzimidazoquinazoline derivatives under mild condition

Supporting Information. Recyclable hypervalent-iodine-mediated solid-phase peptide

Supporting Information

Synergistic Cu-amine catalysis for the enantioselective synthesis of chiral cyclohexenones

Ynamides as racemization-free coupling reagents for amide and peptide synthesis

Supporting Information for. Boronic Acid Functionalized Aza-Bodipy (azabdpba) based Fluorescence Optodes for the. analysis of Glucose in Whole Blood

Supporting Information

Supporting Information

Scheme S1. Synthesis of glycose-amino ligand.

Supplementary Materials Contents

Supporting Information

Supporting Information

Chemo- and Enantioselective Rh-Catalyzed Hydrogenation of 3-Methylene-1,2-diazetidines: Application to Vicinal Diamine Synthesis

The First Au-Nanoparticles Catalyzed Green Synthesis of Propargylamines Via Three-Component Coupling Reaction of Aldehyde, Alkyne And Amine

# Supplementary Material (ESI) for Chemical Communications # This journal is The Royal Society of Chemistry 2005

PREPARATION OF OPTICALLY ACTIVE 2,2-DISUBSTITUTED 5-HYDROXYCHROMENES BY ENZYMATIC RESOLUTION OF RACEMIC ESTERS

Supplemental Material

Electronic Supplementary Information

One-pot Synthesis of 1-Alkyl-1H-indazoles. Supporting Information

Supporting Information. for. Access to pyrrolo-pyridines by gold-catalyzed. hydroarylation of pyrroles tethered to terminal alkynes

Development of a near-infrared fluorescent probe for monitoring hydrazine in serum and living cells

Direct ortho-c H Functionalization of Aromatic Alcohols Masked by Acetone Oxime Ether via exo-palladacycle

Supporting Information

Structure and conserved function of iso-branched sphingoid bases from the nematode Caenorhabditis elegans

Supporting Information. Radical fluorination powered expedient synthesis of 3 fluorobicyclo[1.1.1]pentan 1 amine

Methyltrioxorhenium-Catalyzed Highly Selective Dihydroxylation of 1,2-Allenylic Diphenyl Phosphine Oxides

Supporting Information

Supporting Information. Nitrodibenzofuran: a One- and Two-Photon Sensitive Protecting Group that is Superior to

Supporting Information. Total Synthesis of Grandisine D. Haruaki Kurasaki, Iwao Okamoto, Nobuyoshi Morita, and Osamu Tamura*

Supporting Information

Supporting Information. Use of Potassium. -Trifluoroborato Amides in Suzuki-Miyaura. Cross-Coupling Reactions

Allenylphosphine oxides as simple scaffolds for. phosphinoylindoles and phosphinoylisocoumarins

Synthesis and Assignment of the Absolute Configuration of an Indenotryptoline Bisindole Alkaloid, BE-54017

Supporting Information

Novel D-erythro N-Octanoyl Sphingosine Analogs As Chemo- and Endocrine. Resistant Breast Cancer Therapeutics

Nitro-Grela-type complexes containing iodides. robust and selective catalysts for olefin metathesis

Base-promoted acetal formation employing aryl salicylates

Electronic Supplementary Information

Simple copper/tempo catalyzed aerobic dehydrogenation. of benzylic amines and anilines

Supporting Information. Asymmetric Formation of tert-alkylamines from Serinols by a Dual Function Catalyst

Eur. J. Org. Chem WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, 2007 ISSN X SUPPORTING INFORMATION

Supporting Information. Copyright Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, 2007

Supporting Information. for. Synthesis of dye/fluorescent functionalized. dendrons based on cyclotriphosphazene

On the Utility of S-Mesitylsulfinimines for the Stereoselective Synthesis of Chiral Amines and Aziridines

Supporting Information

Schwartz s reagent-mediated regiospecific synthesis of 2,3-disubstituted indoles from isatins

THE JOURNAL OF ANTIBIOTICS. Polyketomycin, a New Antibiotic from Streptomyces sp. MK277-AF1. II. Structure Determination

Direct Aerobic Carbonylation of C(sp 2 )-H and C(sp 3 )-H Bonds through Ni/Cu Synergistic Catalysis with DMF as the Carbonyl Source

An Unusual Glycosylation Product from a Partially Protected Fucosyl Donor. under Silver Triflate activation conditions. Supporting information

Supporting Information

mm C3a. 1 mm C3a Time (s) C5a. C3a. Blank. 10 mm Time (s) Time (s)

Palladium(II)-Catalyzed Cross-Coupling of Simple Alkenes with Acrylates: A Direct Approach to 1,3-Dienes through C H Activation

Graduate School of Nutritional and Environmental Sciences, University of Shizuoka,

Supporting Information

Naoya Takahashi, Keiya Hirota and Yoshitaka Saga* Supplementary material

Improved Carbonylation of Heterocyclic Chlorides and Challenging Aryl Bromides

NHC-catalyzed cleavage of vicinal diketones and. triketones followed by insertion of enones and

L-Carnosine-Derived Fmoc-Tripeptides Forming ph- Sensitive and Proteolytically Stable Supramolecular

Supporting Information. Palladium-catalyzed reductive cleavage of tosylated arene using isopropanol as the mild reducing agent

Supporting Information

Supplementary Information. Intramolecular 5-exo, 7-endo-dig Transition Metal-Free Cyclization

Supplementary Figures

SUPPORTING INFORMATION. Transition metal-promoted synthesis of 2-aryl/heteroaryl-thioquinazoline: C-S

Transcription:

Supporting information Diversity Oriented Asymmetric Catalysis (DOAC): Stereochemically Divergent Synthesis of Thiochromanes Using an Imidazoline-aminophenol aminophenol (IAP)-Ni Catalyzed Michael/Henry Reaction Takayoshi Arai, Yushi Yamamoto Department of Chemistry, Graduate School of Science, Chiba University, 1-33 Yayoi, Inage, Chiba 263-8522, Japan S1

Contents 1. General S3 2. General procedure for tandem catalytic asymmetric thio Michael/Henry reaction and one pot reduction of nitro group S4 3. Optimization of catalytic Asymmetric thio Michael/Henry reaction S5 4. Reduction of the nitro group of the chiral thiochromanes S7 5. ESI MS analysis of IAP Ni thiolate complex S8 6. Plausible transition state model S9 7. Analytical data of (2S,3R,4R)- 2-aryl-3-nitrothiochroman-4-ols (6) S10 8. Analytical data of (2S,3R,4R)-3-amino-2-arylthiochroman-4-ols (7) S18 9. 1 H NMR and 13 C NMR spectra of (2S,3R,4R)-3-nitro-2-arylthiochroman-4-ols (6) S26 10. 1 H NMR and 13 C NMR spectra of (2S,3R,4R)-3-amino-2-arylthiochroman-4-ols (7) S42 S2

1. General Dry solvents were purchased from commercial suppliers and used without further purification. Analytical thin layer chromatography (TLC) was performed on glass plates coated with 0.25 mm 230 400 mesh silica gel containing a fluorescent indicator (Merck, #1.05715.0009). Silica gel column chromatography was performed on Kanto silica gel 60 (spherical, 100 210 µm). IR spectra were recorded on JASCO FT/IR 4100 using ATR. 1 H NMR spectra were recorded on JEOL ECS 400 (400MHz) or ECA 500 (500MHz) spectrometers. Chemical shifts of 1 H NMR spectra were reported relative to tetramethylsilane (δ 0) or Acetone d 6 (δ 2.05) or DMSO d 6 (δ 2.50). 13 C NMR spectra were recorded on JEOL ECA 400 (100MHz) or ECA 500 (125MHz) spectrometers. Chemical shifts of 13 C NMR spectra were reported relative to CDCl 3 (δ77.0) or Acetone d 6 (δ 29.8) or DMSO d 6 (δ 39.5). Splitting patterns were reported as s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad. General experimental details for synthesis of imidazoline aminophenol ligand (IAP) have been described. 1, 2 Mercaptobenzaldehydes (2-mercaptobenzaldehyde: ca. 75% purity, 5-(tert-butyl)-2-mercaptobenzaldehyde: ca. 86% purity, and 5-chloro-2-mercaptobenzaldehyde: ca. 93% purity) were synthesized according to known procedure. 3 [1] Arai, T.; Yokoyama, N.; Yanagisawa, A. Chem. Eur. J. 2008, 14, 2052. [2] Yokoyama, N.; Arai, T. Chem. Commun. 2009, 3285. [3] Toste, F. D.; Lough, A. J.; Still, W. J. Tetrahedron Lett. 1995, 36, 6619. S3

2. General procedure for tandem catalytic asymmetric thio Michael/Henry reaction and one pot reduction of nitro group IAP1 (0.0165 mmol) and Ni(OAc) 2 4H 2 O (0.015mmol) were added to a two necked round flask containing a stir bir under argon. Anhydrous MeOH (1 ml) was added to the flask and the mixture was stirred for 2 hours. After removal of the solvent under reduced pressure, anhydrous PhMe (1 ml) was added. To the resulting solution, nitroalkene (0.15 mmol) was added at room temperature and cooled to -40 C. Slow addition of 2-mercaptobenzaldehyde (0.225 mmol, ca. 75% purity) in anhydrous PhMe (5 ml) using syringe pump was conducted for 15 hours. After being stirred for appropriate time, the crude mixture was warmed to room temperature. (Procedure A for nitro compound) 0.6 ml of the crude reaction mixture was transferred into another flask via syringe and removed solvent under reduced pressure. Yield and diastereomeric ratio of the nitrothiochromane were determined by crude 1 H NMR. The crude mixture was purified by flash silica gel column chromatography to afford the 2 aryl 3 nitrothiochroman 4 ols. The enantiomeric excesses of the products were determined by chiral stationary phase HPLC using a Daicel Chiralpak AD H, OD H and IC 3 column. (Procedure B for aminoalcohol) After removal of the solvent of the resulting 5.4 ml of crude reaction mixture, dry MeOH (1.2 ml) was added at room temperature under argon. 2.7 mmol of Zn (nanopowder, purchased from Sigma Aldrich) was added. A mixture of 1N aq. HCl (810 µl) and AcOH (405 µl) was added to the heterogeneous solution and stirred for 30 minutes. Zn was filtered out and the filtrate was concentrated by rotary evaporator. CHCl 3 was added to the flask and neutralized by aq. NaHCO 3. The resulting mixture was extracted with CHCl 3 (10 ml x 3) and combined organic layer was dried over Na 2 SO 4. After removal of solvent under reduced pressure, diastereomeric ratio was determined by crude 1 H NMR. The crude mixture was purified by flash silica gel column chromatography to afford the 3 amino 2 arylthiochroman 4 ols. The enantiomeric excesses of the products were determined by chiral stationary phase HPLC using a Daicel Chiralpak AD H, AS H, IA, IC 3, Chiralcel OD H and OJ H column. S4

3. Optimization of reaction condition Table S1. Catalyst screening for thio Michael/Henry reaction. S5

Table S2. Solvent effect for thio Michael/Henry reaction. S6

4. Reduction of the nitro group of the chiral thiochromanes Table S3. Optimization of reduction of the nitro group S7

5. ESI MS analysis of IAP Ni thiolate complex H Ph Ph O Ni-IAP S Ts N N N Ni O S Br + H OHC IAP-Ni-thiolate Ph Br HRMScalcd.forC 45 H 40 Br 2 N 3 NiO 4 S 2 [M+H] + :966.0175 found: m/z = 966.0162 Figure S1. ESI MS analysis of IAP Ni thiolate complex [IAP1 Ni thiolate + H] + species was observed in ESI MS. An ion peak at m/z = 966.0162 corresponds to the [IAP1 (phenoxide) Ni thiolate + H] +. S8

6. Plausible transition state model The formyl group of thiosalicylaldehyde would coordinate to the nickel center because Michael reaction of benzenethiol having no formyl group gave racemic product as shown in Scheme S1. (1.5 eq) SH IAP1(11mol%) Ni(OAc) 2 4H 2 O(10mol%) PhMe(0.025 M) -40 C,20h S Ph 8 86% yield <5%ee NO 2 Ph 5a NO 2 CHO 4a(1.5eq) SH IAP1(11mol%) Ni(OAc) 2 4H 2 O(10mol%) OH NO 2 PhMe(0.025 M) -40 C,16h Scheme S1. Effect of formyl group S Ph 6a >99% yield >99/1 dr 95%ee Figure S2. Plausible transition state model In TS2 (for all trans product), the diheadral angle between C=N and carbonyl C=O is narrow due to a strained thiochromane ring. TS1 having Ni containing chair like six-membered ring is favorable. S9

7. Analytical data of (2S,3R,4R)-2-aryl-3-nitro-thiochroman-4-ols (6) (2S,3R,4R) 3 nitro 2 phenylthiochroman 4 ol (6a) According to the general procedure A, the title compound was obtained by silica gel column chromatography (Hexane : CHCl 3 = 1:1 to 0:1) as a yellow solid. 1 H NMR (500 MHz, Acetone d 6 ) δ 7.61 7.59 (m, 2H), 7.50 7.48 (m, 1H), 7.42 7.39 (m, 2H), 7.37 7.33 (m, 1H), 7.30 (dt, 1H, J = 7.8, 1.5 Hz), 7.20 (dt, 1H, J = 7.5, 1.2 Hz), 7.15 (dd, 1H, J = 8.1, 0.9 Hz), 5.70 (dd, 1H, J = 11.5, 2.9 Hz), 5.46 5.40 (m, 2H), 5.31 (d, 1H, J = 11.8 Hz) ; 13 C NMR (100 MHz, Acetone d 6 ) δ 137.7, 134.6, 133.5, 132.0,129.9, 129.7, 129.3, 129.2, 125.7, 125.4, 90.2, 70.6, 41.4; HRMS calcd for C 15 H 13 NO 3 SNa [M+Na] + : 310.0508, found: m/z 310.0504; Enantiomeric excess was determined by HPLC with a Chiralpak AD H column (85:15 hexane : 2 propanol, 0.7 ml/min, 254 nm); minor 19.2 enantiomer t r = 15.1 min, major enantiomer t r = 22.6 min; 95% ee; [α] D = -231.3 (c = 1.0, MeOH, 98/2 diastereomixture, 95% ee); IR (neat) 3417, 2957, 2925, 2854, 1550, 1315, 1034, 763, 698 cm -1. (2S,3R,4R) 2 (4 chlorophenyl) 3 nitrothiochroman 4 ol (6b) According to the general procedure A, the title compound was obtained by silica gel column chromatography (Hexane : CHCl 3 = 1:1 to AcOEt) as a yellow solid. 1 H NMR (500 MHz, Acetone d 6 ) δ 7.67 7.64 (m, 2H), 7.49 (dd, 1H, J = 7.7, 1.6 Hz), 7.47 7.43 (m, 2H), 7.31 (dt, 1H, J = 7.7, 1.6 Hz), 7.22 7.18 (m, 1H), 7.17 7.15 (m, 1H), 5.70 (dd, 1H, J = 11.6, 2.9 Hz), 5.50 (br, 1H), 5.42 (br, 1H), 5.31 (d, 1H, J = 11.6 Hz); 13 C NMR (125 MHz, Acetone d 6 ) δ 136.8, 134.6, 134.4, 133.3, 132.2, 131.1, 130.1, 139.8, 125.8, 125.4, 89.9, 70.7, 40.6; HRMS calcd for C 15 H 11 NO 3 SCl [M H] : 320.0154, found: m/z 320.0164; Enantiomeric excess was determined by HPLC with a Chiralpak AD H column (85:15 hexane : 2 propanol, 0.7 ml/min, 254 nm); minor enantiomer t r = 16.4 min, major enantiomer t r = 22.6 min; 25.8 94% ee; [α] D = -204.2 (c = 0.1, MeOH, 96/4 diastereomixture, 94% ee); IR (neat) 3190, 2920, 1550, 1491, 1369, 1348, 1090, 1034, 1014, 768 cm -1. S10

(2S,3R,4R) 2 (3 chlorophenyl) 3 nitrothiochroman 4 ol (6c) According to the general procedure A, the title compound was obtained by silica gel column chromatography (Hexane : CHCl 3 = 1:1 to AcOEt) as a yellow amorphous. 1 H NMR (400 MHz, Acetone d 6 ) δ 7.71 (s, 1H), 7.59 (dd, 1H, J = 7.5, 1.1 Hz), 7.50 (d, 1H, J = 7.7 Hz), 7.47 7.43 (m, 1H), 7.41 7.39 (m, 1H), 7.21 (t, 1H, J = 7.5 Hz), 7.16 (d, 1H, J = 7.7 Hz), 5.78 5.74 (m, 1H), 5.51 (br, 1H), 5.43 (br, 1H), 5.32 (d, 1H, J = 11.3 Hz); 13 C NMR (125 MHz, Acetone d 6 ) δ 140.4, 134.9, 134.4, 133.2, 132.2, 131.4, 130.1, 129.4, 129.3, 128.0, 125.8, 125.4, 89.7, 70.7, 40.8; HRMS calcd for C 15 H 11 NO 3 SCl [M H] : 320.0154, found: m/z 320.0166; Enantiomeric excess was determined by HPLC with a Chiralpak OD H column (85:15 hexane : 2 propanol, 0.7 ml/min, 254 nm); minor enantiomer t r = 19.0 min, major enantiomer t r = 25.8 15.8 min; 95% ee; [α] D = -222.4 (c = 0.1, MeOH, 95/5 diastereomixture, 95% ee); IR (neat) 3420, 2921, 1550, 1476, 1366, 1090, 1036, 760, 733 cm -1. (2S,3R,4R) 2 (4 bromophenyl) 3 nitrothiochroman 4 ol (6d) According to the general procedure A, the title compound was obtained by silica gel column chromatography (Hexane : CHCl 3 = 1:1 to AcOEt) as a yellow solid. 1 H NMR (400 MHz, Acetone d 6 ) δ 7.59 (s, 4H), 7.49 (dd, 1H, J = 7.8, 1.4 Hz), 7.31 (dt, 1H, J = 7.8, 1.4 Hz), 7.20 (dt, 1H, J = 7.6, 1.2 Hz), 7.17 7.14 (m, 1H), 5.70 (dd, 1H, J = 11.7, 3.0 Hz), 5.50 (br, 1H), 5.42 (d, 1H, J = 2.5 Hz), 5.29 (d, 1H, J = 11.7 Hz); 13 C NMR (125 MHz, Acetone d 6 ) δ 137.3, 134.4, 133.2, 132.7, 132.2, 131.4, 130.0, 125.8, 125.3, 122.7, 89.8, 70.6, 40.6; HRMS calcd for C 15 H 11 NO 3 SBr [M H] : 363.9648, found: m/z 363.9662; Enantiomeric excess was determined by HPLC with a Chiralpak IC 3 column (85:15 hexane : 2 propanol, 0.7 ml/min, 254 nm); minor 24.4 enantiomer t r = 30.6 min, major enantiomer t r = 11.7 min; 93% ee; [α] D = -200.5 (c = 0.1, MeOH, 97/3 diastereomixture, 93% ee); IR (neat) 3734, 1547, 1475, 1072, 1034, 1011, 765 cm -1. S11

(2S,3R,4R) 2 (3 bromophenyl) 3 nitrothiochroman 4 ol (6e) According to the general procedure A, the title compound was obtained by silica gel column chromatography (Hexane : CHCl 3 = 1:1 to AcOEt) as a brown solid. 1 H NMR (500 MHz, Acetone d 6 ) δ 7.86 7.85 (m, 1H), 7.64 (dt, 1H, J = 7.7, 1.2 Hz), 7.56 7.54 (m, 1H), 7.50 (dd, 1H, J = 7.5, 1.4 Hz), 7.38 (t, 1H, J = 7.9 Hz), 7.31 (dt, 1H, J = 7.7, 1.4 Hz), 7.21 (dt, 1H, J = 7.5, 1.4 Hz), 7.16 (dd, 1H, J = 7.7, 1.2 Hz), 5.77 5.74 (m, 1H), 5.49 (br, 1H), 5.43 (br, 1H), 5.30 (d, 1H, J = 11.5 Hz); 13 C NMR (125 MHz, CDCl 3 ) δ 137.7, 123.3, 132.1, 131.6, 131.4, 130.9 130.5 130.0 127.2 125.4 125.2 122.9, 89.6, 70.0, 40.4; HRMS calcd for C 15 H 11 NO 3 SBr [M H] :363.9648, found: m/z 363.9659; Enantiomeric excess was determined by HPLC with a Chiralpak AD H column (85:15 hexane : 2 propanol, 0.7 ml/min, 254 nm); minor enantiomer t r = 24.7 15.2 min, major enantiomer t r = 21.2 min; 94% ee; [α] D = -168.4 (c = 0.1, MeOH, 97/3 diastreomixture, 94% ee); IR (neat) 3335, 2958, 1555, 1523, 1474, 1331, 1075, 1037, 768 cm -1. (2S,3R,4R) 2 (4 fluorophenyl) 3 nitrothiochroman 4 ol (6f) According to the general procedure A, the title compound was obtained by silica gel column chromatography (Hexane : CHCl 3 = 1:1 to AcOEt) as a pale yellow amorphous. 1 H NMR (400 MHz, Acetone d 6 ) δ 7.70 7.65 (m, 2H), 7.49 (dd, 1H, J = 7.7, 1.4 Hz), 7.33 7.28 (m, 1H), 7.22 7.14 (m, 4H), 5.68 (dd, 1H, J = 11.6, 2.9 Hz), 5.48 (br, 1H), 5.41 (d, 1H, J = 2.5 Hz), 5.31 (d, 1H, J = 11.6 Hz); 13 C NMR (100 MHz, Acetone d 6 ) δ 163.4 (d, J = 246.1 Hz), 134.4, 133.9 (d, J = 2.9 Hz), 133.4, 132.1, 131.4 (d, J = 8.6 Hz), 130.0, 125.7, 125.4, 116.5 (d, J = 21.0 Hz), 90.1, 70.7, 40.5; HRMS calcd for C 15 H 11 NO 3 SF [M H] : 304.0449, found: m/z 304.0461; Enantiomeric excess was determined by HPLC with a Chiralpak IA column (95:5 hexane : 2 propanol, 1.0 ml/min, 254 nm); minor enantiomer t r = 31.0 min, major enantiomer 25.8 t r = 37.6 min; 90% ee; [α] D = -174.6 (c = 0.1, MeOH, 95/5 diastereomixture, 90% ee); IR (neat) 3734, 3419, 2924, 1552, 1508, 1315, 1227, 1035, 760 cm -1. S12

(2S,3R,4R) 3 nitro 2 (4 nitrophenyl)thiochroman 4 ol (6g) According to the general procedure A, the title compound was obtained by silica gel column chromatography (Hexane : CHCl 3 = 1:1 to 0:1) as a yellow solid. 1 H NMR (500 MHz, Acetone d 6 ) δ 8.30 8.27 (m, 2H), 7.95 7.93 (m, 2H), 7.52 7.50 (m, 1H), 7.32 (dt, 1H, J = 7.5, 1.4 Hz), 7.23 (dt, 1H, J = 7.5, 1.2 Hz), 7.18 7.17 (m, 1H), 5.83 5.50 (m, 1H), 5.60 (d, 1H, J = 5.2 Hz), 5.49 5.45 (m, 2H); 13 C NMR (125 MHz, Acetone d 6 ) δ 148.8, 145.5, 134.4, 132.7, 132.3, 130.7, 130.2, 126.0, 125.3, 124.8, 89.5, 70.6, 40.6; HRMS calcd for C 15 H 11 NO 3 SCl [M+Cl] : 367.0161, found: m/z 367.0173; Enantiomeric excess was determined by HPLC with a Chiralcel OD H column (80:20 hexane : 2 propanol, 0.7 ml/min, 254 nm); minor enantiomer t r = 49.3 min, major enantiomer t r = 37.3 min; 26.9 91% ee; [α] D = -224.3 (c = 0.2, MeOH, 91% ee); IR (neat) 3149, 3029, 2811, 1556, 1524, 1349, 1046, 764 cm -1. (2S,3R,4R) 3 nitro 2 (3 nitrophenyl)thiochroman 4 ol (6h) According to the general procedure A, the title compound was obtained by silica gel column chromatography (Hexane : CHCl 3 = 1:1 to AcOEt) as a yellow solid. 1 H NMR (400 MHz, Acetone d 6 ) δ 8.55 (t, 1H, J = 2.0 Hz), 8.26 8.24 (m, 1H), 8.12 (d, 1H, J = 7.7 Hz), 7.77 7.73 (m, 1H), 7.53 7.50 (m, 1H), 7.33 (dt, 1H, J = 7.7, 1.4 Hz), 7.23 (dt, 1H, J = 7.5, 1.1 Hz), 7.19 (d, 1H, J = 7.7 Hz), 5.90 (dd, 1H, J = 11.6, 2.9 Hz), 5.59 (d, 1H, J = 5.0 Hz), 5.52 5.48 (m, 2H); 13 C NMR (100 MHz, Acetone d 6 ) δ149.4, 140.4, 135.9, 134.4, 133.7, 132.8, 132.3, 131.1, 130.2, 125.9, 125.3, 124.2, 89.5, 70.7, 40.6; HRMS calcd for C 15 H 12 N 2 O 5 SCl [M+Cl] :367.0161, found: m/z367.0171; Enantiomeric excess was determined by HPLC with a Chiralpak IA column (90:10 hexane : 2 propanol, 1.0 ml/min, 254 nm); minor enantiomer t r = 36.1 20.4 min, major enantiomer t r = 44.1 min; 92% ee; [α] D = -94.6 (c = 0.1, MeOH, 97/3 diastereomixture, 93% ee); IR (neat) 3734, 3649, 3361, 3195, 2921, 2851, 1554, 1527, 1350, 1037, 758, 686 cm -1. S13

(2S,3R,4R) 2 (4 methoxyphenyl) 3 nitrothiochroman 4 ol (6i) According to the general procedure A, the title compound was obtained by silica gel column chromatography (Hexane : CHCl 3 = 1:1 to 0:1) as a yellow solid. 1 H NMR (500 MHz, Acetone d 6 ) δ 7.53 7.50 (m, 2H), 7.47 (dd, 1H, J = 7.8, 1.5 Hz), 7.29 (dt, 1H, J = 7.5, 1.4 Hz), 7.19 (dt, 1H, J = 7.5, 1.2 Hz), 7.14 (dd, 1H, J = 8.0, 1.2 Hz), 6.96 6.93 (m, 2H), 5.62 (dd, 1H, J = 11.5, 2.9 Hz), 5.44 5.37 (m, 2H), 5.25 (d, 1H J = 11.8 Hz), 3.79 (s, 3H); 13 C NMR (125 MHz, Acetone d 6 ) δ 160.7, 134.5, 133.9, 132.1, 130.5, 129.9, 129.2, 125.6, 125.4, 115.0, 90.4, 70.8, 55.5, 40.9; HRMS calcd for C 16 H 14 NO 4 S [M H] :316.0649, found: m/z 316.0659; Enantiomeric excess was determined by HPLC with a Chiralpak AD H column (85:15 hexane : 2 propanol, 0.7 ml/min, 254 nm); minor 26.6 enantiomer t r = 22.5 min, major enantiomer t r = 35.4 min; 84% ee; [α] D = -223.5 (c = 0.2, MeOH, 95/5 diastereomixture, 84% ee); IR (neat) 2927, 1558, 1513, 1308, 1255, 1176, 1033, 757 cm -1. (2S,3R,4R) 2 (3 methoxyphenyl) 3 nitrothiochroman 4 ol (6j) According to the general procedure A, the title compound was obtained by silica gel column chromatography (Hexane : CHCl 3 = 1:1 to AcOEt) as a yellow solid. 1 H NMR (400 MHz, Acetone d 6 ) δ 7.48 (dd, 1H, J = 7.7, 1.4 Hz), 7.33 7.28 (m, 2H), 7.20 (dd, 1H, J = 7.5, 1.4 Hz), 7.18 7.14 (m, 3H), 6.93 6.90 (m, 1H), 5.73 5.69 (m, 1H), 5.48 (br, 1H), 5.40 (br, d, 1H, J = 2.7 Hz), 5.25 (d, 1H, J = 11.6 Hz), 3.82 (s, 3H); 13 C NMR (100 MHz, Acetone d 6 ) δ 160.9, 139.3, 134.5, 133.7, 132.1, 130.7, 130.0, 125.7, 125.4, 121.4, 114.9, 114.7, 90.0, 70.7, 55.6, 41.4; HRMS calcd for C 16 H 14 NO 4 S [M H] :316.0649, found: m/z 316.0660; Enantiomeric excess was determined by HPLC with a Chiralpak AD H column (85:15 hexane : 2 propanol, 0.7 ml/min, 254 nm); minor enantiomer t r = 22.0 19.6 min, major enantiomer t r = 39.3 min; 92% ee; [α] D = -149.3 (c = 1.0, MeOH, 98/2 diastereomixture, 94% ee); IR (neat) 2926, 1551, 1317, 1261, 1035, 756 cm -1. S14

(2S,3R,4R) 3 nitro 2 (p tolyl)thiochroman 4 ol (6k) According to the general procedure A, the title compound was obtained by silica gel column chromatography (Hexane : CHCl 3 = 1:1 to 0:1) as a yellow solid. 1 H NMR (400 MHz, Acetone d 6 ) δ 7.49 7.46 (m, 3H), 7.29 (dt, 1H, J = 7.5, 1.4 Hz), 7.22 7.17 (m, 3H), 7.14 (dd, 1H, J = 7.9, 1.1 Hz), 5.66 (dd, 1H, J = 11.6, 2.9 Hz), 5.44 5.39 (br, 2H), 5.24 (d, 1H, J = 11.6 Hz), 2.32 (s, 3H); 13 C NMR (100 MHz, Acetone d 6 ) δ139.1, 134.6, 134.5, 133.8, 132.1, 130.3, 130.0, 129.2, 125.6, 125.4, 90.3, 70.7, 41.1, 21.1; HRMS calcd for C 16 H 14 NO 3 S [M H] : 300.0700, found: m/z 300.0710; Enantiomeric excess was determined by HPLC with a Chiralpak AD H column (80:20 hexane : 2 propanol, 0.7 ml/min, 254 nm); minor enantiomer t r =11.3 min, 20.3 major enantiomer t r = 19.0 min; 84% ee; [α] D = -123.7 (c = 0.1, MeOH, 91/9 diastereomixture, 84% ee); IR (neat) 2919, 1552, 1474, 1369, 1035, 760 cm -1. (2S,3R,4R) 3 nitro 2 (m tolyl)thiochroman 4 ol (6l) According to the general procedure A, the title compound was obtained by silica gel column chromatography (Hexane : CHCl 3 = 1:1 to AcOEt) as an orange amorphous. 1 H NMR (400 MHz, CDCl 3 ) δ 7.40 7.38 (m, 1H), 7.32 7.23 (m, 4H), 7.20 7.13 (m, 3H), 5.35 5.25 (m, 3H), 2.88 (br, 1H), 2.35 (s, 3H); 13 C NMR (100 MHz, CDCl 3 ) δ 138.7, 135.2, 132.9, 131.7, 130.8, 129.7 (2C), 129.1, 128.8, 125.4, 125.5, 125.4, 89.9, 70.0, 41.0, 21.3; HRMS calcd for C 16 H 14 NO 3 S [M H] : 300.0700, found: m/z 300.0713; Enantiomeric excess was determined by HPLC with a Chiralpak AD H column (90:10 hexane : 2 propanol, 0.7 ml/min, 254 23.7 nm); minor enantiomer t r = 19.1 min, major enantiomer t r = 29.1 min; 94% ee; [α] D = -139.8 (c = 0.1, MeOH, 96/4 diastereomixture, 94% ee); IR (neat) 3158, 1557, 1520, 1317, 1038, 760 cm -1. S15

(2R,3R,4R) 3 nitro 2 (thiophen 2 yl)thiochroman 4 ol (6m) According to the general procedure A, the title compound was obtained by silica gel column chromatography (Hexane : CHCl 3 = 1:1 to AcOEt) as a yellow solid. 1 H NMR (400 MHz, Acetone d 6 ) δ 7.50 7.48 (m, 2H), 7.34 7.32 (m, 1H), 7.32 7.29 (m, 1H), 7.21 (dt, 1H, J = 7.5, 1.4 Hz), 7.18 7.16 (m, 1H), 7.04 (dd, 1H, J = 5.2, 1.6 Hz), 5.61 (d, 1H, J = 11.4 Hz), 5.54 (dd, 1H, J = 11.2, 2.8 Hz), 5.48 (br, 1H), 5.38 (d, 1H, J = 2.8 Hz); 13 C NMR (100 MHz, Acetone d 6 ) δ 140.3, 134.4, 133.3, 131.8, 130.0, 128.6, 128.0, 127.2, 125.9, 125.4, 91.8, 70.8, 37.3; HRMS calcd for C 13 H 10 NO 3 S 2 [M H] : 292.0108, found: m/z 292.0121; Enantiomeric excess was determined by HPLC with a Chiralpak AD H column (85:15 hexane : 2 propanol, 1.0 ml/min, 254 nm); minor enantiomer t r = 12.1 min, major enantiomer t r = 15.4 min; 24.1 94% ee; [α] D = -171.9 (c = 0.1, MeOH, 91/9 diastereomixture, 94% ee); IR (neat) 2922, 1552, 1518, 1315, 1077, 1032, 757, 733 cm -1. (2S,3R,4R) 6 chloro 3 nitro 2 phenylthiochroman 4 ol (6n) According to the general procedure A, the title compound was obtained by silica gel column chromatography (Hexane : CHCl 3 = 1:1 to AcOEt) as a yellow solid. 1 H NMR (400 MHz, Acetone d 6 ) δ 7.62 7.59 (m, 2H), 7.56 (d, 1H, J = 2.2 Hz), 7.44 7.33 (m, 4H), 7.21 (d, 1H, J = 8.7 Hz), 5.75 (dd, 1H, J = 11.2, 3.1 Hz), 5.65 (br, 1H), 5.43 (d, 1H, J = 2.5 Hz), 5.26 (d, 1H, J = 11.4 Hz); 13 C NMR (100 MHz, Acetone d 6 ) δ 137.5, 136.7, 132.7, 131.4, 130.7, 129.9, 129.8, 129.5, 129.3, 127.3, 90.1, 70.2, 42.0; HRMS calcd for C 15 H 11 NO 3 SCl [M H] : 320.0154, found: m/z 320.0166; Enantiomeric excess was determined by HPLC with a Chiralcel OD H column (85:15 hexane : 2 propanol, 0.5 ml/min, 254 nm); minor 25.0 enantiomer t r = 25.2 min, major enantiomer t r = 27.4 min; 80% ee; [α] D = -131.0 (c = 0.1, MeOH, 84/16 diastereomixture, 80% ee); IR (neat) 3734, 3649, 2923, 2852, 1556, 1456, 1362, 1102, 696 cm -1. S16

(2S,3R,4R) 6 (tert butyl) 3 nitro 2 phenylthiochroman 4 ol (6o) According to the general procedure A, the title compound was obtained by silica gel column chromatography (Hexane : CHCl 3 = 1:1 to AcOEt) as a yellow amorphous. 1 H NMR (400 MHz, Acetone d 6 ) δ 7.61 7.59 (m, 2H), 7.55 (d, 1H, J = 2.0 Hz), 7.43 7.34 (m, 4H), 7.09 7.06 (m, 1H), 5.70 5.66 (m, 1H), 5.41 (br, 2H), 5.28 (d, 1H, J = 11.7 Hz), 1.32 (s, 9H); 13 C NMR (100 MHz, CDCl 3 ) δ 148.6, 135.4, 131.0, 129.4, 129.1, 129.0, 128.9, 128.5, 128.1, 127.7, 127.4, 125.0, 90.2, 70.5, 40.9, 34.4, 31.2; HRMS calcd for C 19 H 20 NO 3 S [M H] :342.1169, found: m/z 342.1179; Enantiomeric excess was determined by HPLC with a Chiralpak AD H column (90:10 hexane : 2 propanol, 0.7 ml/min, 254 25.8 nm); minor enantiomer t r = 18.4 min, major enantiomer t r = 14.2 min; 87% ee; [α] D = -150.5 (c = 0.1, MeOH, 91/9 diastereomixture, 87% ee); IR (neat) 3735, 3649, 2962, 2904, 1556, 1485, 1457, 1361, 697 cm -1. (2S,3R,4R) 3 nitro 2 pentylthiochroman 4 ol (6p) According to the general procedure A, the title compound was obtained by silica gel column chromatography (Hexane : CHCl 3 = 1:1 to 0:1) as a yellow oil. 1 H NMR (400 MHz, CDCl 3 ) δ 7.39 7.36 (m, 1H), 7.27 7.14 (m, 3H), 5.14 (s, 1H), 4.86 (dd, 1H, J = 9.5, 2.6 Hz), 4.13 (dt, 1H, J = 9.5, 4.0 Hz), 2.98 (d, 1H, J = 4.9 Hz), 1.79 1.25 (m, 8H), 0.92 0.87 (m, 3H); 13 C NMR (125 MHz, CDCl 3 ) δ 129.6, 129.5, 128.5, 126.6, 125.3, 90.2, 69.7, 38.0, 32.6, 31.2, 25.7, 22.3, 13.9; HRMS calcd for C 14 H 18 NO 3 S [M H] : 280.1013, found: m/z 280.1025; Enantiomeric excess was determined by HPLC with a Chiralpak AD H column (95:5 hexane : 2 propanol, 0.7 ml/min, 254 nm); minor enantiomer t r = 20.0 min, major enantiomer t r = 32.9 min; 4% ee; IR (neat) 3734, 3649, 3393, 2955, 2927, 2857, 1556, 1456, 1375, 1079, 1038, 750, 696 cm -1. S17

8. Analytical data of (2S,3R,4R)-3-amino-2-arylthiochroman-4-ols (7) (2S,3R,4R) 3 amino 2 phenylthiochroman 4 ol (7a) According to the general procedure B, the title compound was obtained by silica gel column chromatography (AcOEt to CHCl 3 : MeOH = 10:1) as a white solid. 1 H NMR (500 MHz, DMSO d 6 ) δ 7.46 7.44 (m, 2H), 7.39 (t, 2H, J = 7.5 Hz), 7.34 7.31 (m, 2H), 7.18 (dt, 1H, J = 7.5, 1.4 Hz), 7.10 7.07 (m, 2H), 4.55 (d, 1H, J = 2.6 Hz), 4.43 (d, 1H, J = 10.0 Hz), 3.31 (dd, 1H, J = 10.0, 2.6 Hz); 13 C NMR (125 MHz, DMSO d 6 ) δ 139.0, 136.2, 133.1, 131.2, 129.2, 128.7, 128.1, 127.8, 124.4, 123.9, 69.7, 54.8, 46.0; HRMS calcd for C 15 H 16 NOS [M+H] + :258.0947, found: m/z 258.0945; Enantiomeric excess was determined by HPLC with a Chiralpak AD H column and Chiralcel OD H column (90:10 hexane : 2 propanol, 0.7 ml/min, 254 29.2 nm); minor enantiomer t r = 50.9 min, major enantiomer t r = 43.9 min; 96% ee; [α] D = -178.9 (c = 1.0, MeOH, 96% ee); IR (neat) 3734, 3649, 3134, 2878, 1560, 1472, 1104, 1078, 872, 698 cm -1. (2S,3R,4R) 3 amino 2 (4 chlorophenyl)thiochroman 4 ol (7b) According to the general procedure B, the title compound was obtained by silica gel column chromatography (hexane: AcOEt = 2:1 to CHCl 3 : MeOH = 10:1) as a white solid. 1 H NMR (500 MHz, CDCl 3 ) δ 7.40 7.35 (m, 5H), 7.23 7.20(m, 1H), 7.15 7.11 (m, 2H), 4.69 (d, 1H, J = 2.6 Hz), 4.44 (d, 1H, J = 9.7 Hz), 3.50 (d, 1H, J = 8.6 Hz), 2.04 (br, 3H); 13 C NMR (125 MHz, CDCl 3 ) δ 136.6, 134.1, 134.0, 133.3, 131.2, 130.3, 129.2, 128.8, 125.2, 124.7, 70.0, 55.3, 46.1; HRMS calcd for C 15 H 15 NOSCl [M+H] + :292.0557, found: m/z 292.0553; Enantiomeric excess was determined by HPLC with a Chiralcel OD H column (97.5 : 2.5 hexane : 2 propanol, 1.0 ml/min, 254 nm); minor enantiomer t r = 62.4 min, major enantiomer t r = 38.8 min; 25.8 95% ee; [α] D = -166.9 (c = 0.5, MeOH, 95% ee); IR (neat) 3734, 3649, 3375, 3066, 2875, 1490, 1088, 1012, 849, 752 cm -1. S18

(2S,3R,4R) 3 amino 2 (3 chlorophenyl)thiochroman 4 ol (7c) According to the general procedure B, the title compound was obtained by silica gel column chromatography (hexane: AcOEt = 2:1 to CHCl 3 : MeOH = 10:1) as a pale yellow solid. 1 H NMR (400 MHz, DMSO d 6 ) δ 7.51 (s, 1H), 7.43 7.36 (m, 3H), 7.32 (d, 1H, J = 7.5 Hz), 7.19 (dt, 1H, J = 7.7, 1.4 Hz), 7.10 7.07 (m, 2H), 4.53 (d, 1H, J = 2.5 Hz), 4.45 (d, 1H, J = 10.2 Hz), 3.32 (dd, 1H, J = 10.2 H; 13 C NMR (100 MHz, DMSO d 6 ) δ 141.9, 136.2, 133.1, 132.7, 131.1, 130.4, 129.0, 128.2, 128.0, 127.7, 124.3, 124.0, 69.9, 54.6, 45.6; HRMS calcd for C 15 H 15 NOSCl [M+H] + :292.0557, found: m/z 292.0556; Enantiomeric excess was determined by HPLC with a Chiralpak AD H and AS H column (93 : 7 hexane : 2 propanol, 0.7 25.8 ml/min, 254 nm); minor enantiomer t r = 63.6 min, major enantiomer t r = 43.3 min; 98% ee; [α] D = -151.6 (c = 0.25, MeOH, 98% ee); IR (neat) 3734, 3649, 3374, 3055, 2920, 2850, 1568, 1106, 1076, 780, 754 cm -1. (2S,3R,4R) 3 amino 2 (4 bromophenyl)thiochroman 4 ol (7d) According to the general procedure B, the title compound was obtained by silica gel column chromatography (hexane: AcOEt = 2:1 to CHCl 3 : MeOH = 10:1) as a white crystalline solid. 1 H NMR (400 MHz, CDCl 3 ) δ 7.53 7.50 (m, 2H), 7.39 (d, 1H, J = 7.6 Hz), 7.35 7.32 (m, 2H), 7.24 7.20 (m, 1H), 7.15 7.10 (m, 2H), 4.69 (d, 1H, J = 2.9 Hz), 4.43 (d, 1H, J = 9.7 Hz), 3.50 (dd, 1H, J = 9.7, 2.7 Hz), 1.95 (br, 3H); 13 C NMR (100 MHz, CDCl 3 ) δ 137.2, 134.0, 133.3, 132.2, 131.1, 130.7, 128.8, 125.2, 124.7, 122.3, 70.0, 55.3, 46.2; HRMS calcd for C 15 H 15 NOSBr [M+H] + :336.0052, found: m/z 336.0050; Enantiomeric excess was determined by HPLC with a Chiralcel OD H column (90 : 10 hexane : 2 propanol, 0.7 ml/min, 25.5 254 nm); minor enantiomer t r = 19.5 min, major enantiomer t r = 14.8 min; 93% ee; [α] D = -136.9 (c = 0.25, MeOH, 93% ee); IR (neat) 3734, 3649, 3375, 3065, 2875, 1569, 1486, 1472, 1071, 1009, 793, 752, 728 cm -1. S19

(2S,3R,4R) 3 amino 2 (3 bromophenyl)thiochroman 4 ol (7e) According to the general procedure B, the title compound was obtained by silica gel column chromatography (hexane: AcOEt = 2:1 to CHCl 3 : MeOH = 10:1) as a white solid. 1 H NMR (500 MHz, DMSO d 6 ) δ 7.65 (t, 1H, J = 1.7 Hz), 7.53 7.50 (m, 1H), 7.47 (d, 1H, J = 8.0 Hz), 7.36 7.31 (m, 2H), 7.19 (dt, 1H, J = 7.7, 1.4 Hz), 7.11 7.07 (m, 2H), 5.56 (br, 1H), 4.53 (br, 1H), 4.44 (d, 1H, J = 10.0 Hz), 3.32 3.30 (m, 1H), 1.48 (br, 2H); 13 C NMR (125 MHz, DMSO d 6 ) δ 142.2, 136.2, 132.7, 131.8, 131.1, 130.7, 130.6, 128.3, 128.1, 124.3, 124.0, 121.7, 69.9, 54.6, 45.5; HRMS calcd for C 15 H 15 NOSBr [M+H] + :336.0052, found: m/z 336.0050; Enantiomeric excess was determined by HPLC with a Chiralpak AD H column (95 : 5 hexane : 2 propanol, 0.7 ml/min, 254 nm); minor enantiomer t r = 25.2 39.2 min, major enantiomer t r = 30.8 min; 98% ee; [α] D = -130.9 (c = 0.1, MeOH, 98% ee); IR (neat) 3734, 3649, 3369, 3053, 2894, 2841, 1566, 1471, 1324, 1073, 1011, 919, 779, 756, 687 cm -1 (2S,3R,4R) 3 amino 2 (4 fluorophenyl)thiochroman 4 ol (7f) According to the general procedure B, the title compound was obtained by silica gel column chromatography (hexane: AcOEt = 2:1 to CHCl 3 : MeOH = 10:1) as a yellow solid. 1 H NMR (500 MHz, CDCl 3 ) δ 7.45 7.42 (m, 2H), 7.40 (d, 1H, J = 7.7 Hz), 7.23 7.20 (m, 1H), 7.15 7.06 (m, 4H), 4.71 (d, 1H, J = 2.9 Hz), 4.46 (d, 1H, J = 9.7 H), 3.53 3.50 (m, 1H), 2.02 (br, 3H); 13 C NMR (125 MHz, CDCl 3 ) δ 134.0, 133.5, 131.2, 130.7, 130.6, 128.8, 125.3, 124.7, 116.1, 115.9, 70.1, 55.5, 46.0; HRMS calcd for C 15 H 15 N 2 OSF [M+H] + :276.0853, found: m/z 276.0848; Enantiomeric excess was determined by HPLC with a Chiralcel OD H column (97.5 : 2.5 hexane : 2 propanol, 1.0 ml/min, 254 nm); minor 25.8 enantiomer t r = 55.4 min, major enantiomer t r = 35.6 min; 92% ee; [α] D = -140.3 (c = 0. 5, MeOH, 92% ee); IR (neat) 3734, 3649, 3384, 2924, 2880, 2852, 1599, 1507, 1473, 1212, 1159, 1108, 856, 789, 757 cm -1 S20

(2S,3R,4R) 3 amino 2 (4 methoxyphenyl)thiochroman 4 ol (7g) According to the general procedure B, the title compound was obtained by silica gel column chromatography (hexane: AcOEt = 2:1 to CHCl 3 : MeOH = 10:1) as pale a yellow solid. 1 H NMR (400 MHz, CDCl 3 ) δ 7.37 7.35 (m, 3H), 7.21 7.18 (m, 1H), 7.14 7.08 (m, 2H), 6.91 (d, 2H, J = 8.6 Hz), 4.72 (d, 1H, J = 2.0 Hz), 4.42 (d, 1H, J = 10.0 Hz), 3.82 (s, 3H), 3.49 (dd, 1H, J = 10.0, 2.5 Hz), 2.37 (br, 3H); 13 C NMR (100 MHz, CDCl 3 ) δ 159.5, 134.2, 133.9, 131.3, 130.1, 129.5, 128.6, 125.2, 124.4, 70.1, 55.3, 45.6, 29.7; HRMS calcd for C 16 H 18 NO 2 S [M+H] + : 288.1053, found: m/z 288.1039; Enantiomeric excess was determined by HPLC with a Chiralcel OJ H column (90 : 10 hexane : 2 propanol, 1.0 ml/min, 254 nm); minor enantiomer t r = 31.7 min, major enantiomer t r = 22.9 min; 25.8 83% ee; [α] D = -148.9 (c = 0.25, MeOH, 83% ee); IR (neat) 3734, 3649, 2901, 2834, 1608, 1509, 1249, 1175, 1028, 754, 731 cm -1 (2S,3R,4R) 3 amino 2 (3 methoxyphenyl)thiochroman 4 ol (7h) According to the general procedure B, the title compound was obtained by silica gel column chromatography (hexane: AcOEt = 2:1 to CHCl 3 : MeOH = 10:1) as a slightly yellow solid. 1 H NMR (500 MHz, DMSO d 6 ) δ 7.32 7.28 (m, 2H), 7.18 (dt, 1H, J = 7.5, 1.4 Hz), 7.10 7.06 (m, 2H), 6.90 6.88 (m, 2H), 4.54 (d, 1H, J = 2.3 Hz), 4.40 (d, 1H, J = 10.0 Hz), 3.76 (s, 3H), 3.32 (br, 3H), 3.31 3.28 (m, 1H); 13 C NMR (125 MHz, DMSO d 6 ) δ 159.4, 140.6, 136.1, 133.1, 131.2, 129.8, 128.1, 124.4, 123.9, 121.3, 114.7, 113.3, 69.7, 55.1, 54.8, 46.1; HRMS calcd for C 16 H 18 NO 2 S [M+H] + : 288.1053, found: m/z 288.1049; Enantiomeric excess was determined by HPLC with a Chiralcel AS H column (95 : 5 hexane : 2 propanol, 0.7 ml/min, 254 nm); minor enantiomer t r = 78.0 min, major enantiomer t r = 29.8 58.5 min; 99% ee; [α] D = -136.5 (c = 0.25, MeOH, 99% ee); IR (neat) 3739, 3649, 3370, 2955, 2917, 2851, 1596, 1490, 1469, 1265, 1161, 775, 755 cm -1 S21

(2S,3R,4R) 3 amino 2 (p tolyl)thiochroman 4 ol (7i) According to the general procedure B, the title compound was obtained by silica gel column chromatography (AcOEt to CHCl 3 : MeOH = 5:1) as a slightly yellow solid. 1 H NMR (400 MHz, CDCl 3 ) δ 7.39 (d, 1H, J = 7.4 Hz), 7.33 (d, 2H, J = 8.1 Hz), 7.19 (d, 3H, J = 7.4 Hz), 7.15 7.09 (m, 2H), 4.72 (d, 1H, J = 2.5 Hz), 4.43 (d, 1H, J = 10.1 Hz), 3.55 3.52 (m, 1H), 2.48 (br, 3H), 2.36 (s, 3H); 13 C NMR (100 MHz, CDCl 3 ) δ 138.2, 134.8, 134.1, 133.9, 131.2, 129.7, 128.9, 128.7, 125.2, 124.5, 70.1, 55.4, 46.2, 21.1; HRMS calcd for C 16 H 18 NOS [M+H] + :272.1104, found: m/z 272.1097; Enantiomeric excess was determined by HPLC with a Chiralcel OJ H column (90 : 10 hexane : 2 propanol, 0.7 ml/min, 20.6 254 nm); minor enantiomer t r = 32.7 min, major enantiomer t r = 20.2 min; 91% ee; [α] D = -130.2 (c = 0.25, MeOH, 91% ee); IR (neat) 3734, 3649, 3377, 2918, 1510, 775, 754 cm -1 (2S,3R,4R) 3 amino 2 (m tolyl)thiochroman 4 ol (7j) According to the general procedure B, the title compound was obtained by silica gel column chromatography (hexane : AcOEt = 2:1 to CHCl 3 : MeOH = 5:1) as a white solid. 1 H NMR (400 MHz, CDCl 3 ) δ 38 (d, 1H, J = 7.5 Hz), 7.29 7.22 (m, 3H), 7.20 7.18 (m, 1H), 7.14 7.09 (m, 3H), 4.74 (s, 1H), 4.42 (d, 1H, J = 10.0 Hz), 3.55 (d, 1H, J = 9.7 Hz), 2.81 (br, 3H); 13 C NMR (100 MHz, CDCl 3 ) δ 138.7, 137.8, 134.1, 133.8, 131.2, 129.7, 129.1, 128.9, 128.7, 126.1, 125.2, 124.5, 70.2, 55.4, 46.5, 21.4; HRMS calcd for C 16 H 17 NOS [M+H] + :272.1104, found: m/z 272.1103; Enantiomeric excess was determined by HPLC with a Chiralcel IC 3 and AD H column (95 : 5 hexane : 2 propanol, 0.6 ml/min, 254 24.6 nm); minor enantiomer t r = 98.1 min, major enantiomer t r = 62.7 min; >99% ee; [α] D = -165.3 (c = 0.25, MeOH, >99% ee); IR (neat) 3734, 3649, 3375, 2987, 2891, 1568, 1470, 1075, 1013, 768, 753 cm -1 S22

(2R,3R,4R) 3 amino 2 (thiophen 2 yl)thiochroman 4 ol (7k) According to the general procedure B, the title compound was obtained by silica gel column chromatography (hexane : AcOEt = 2:1 to CHCl 3 : MeOH = 5:1) as a white solid. 1 H NMR (400 MHz, CDCl 3 ) δ 7.38 (d, 1H, J = 7.7 Hz), 7.32 (dd, 1H, J = 5.2, 0.9 Hz), 7.23 7.19 (m, 1H), 7.14 7.09 (m, 3H), 7.01 6.99 (m, 1H), 4.77 (d, 1H, J = 9.5 Hz), 4.72 (d, 1H, J = 2.7 Hz), 3.45 (dd, 1H, J = 9.5, 2.7 Hz), 2.28 (br, 3H); 13 C NMR (100 MHz, CDCl 3 ) δ 141.8, 133.9, 133.2, 131.1, 128.7, 127.4, 127.0, 126.1, 125.1, 124.7, 70.0, 56.8, 42.5; HRMS calcd for C 13 H 14 NOS 2 [M+H] + :264.0511, found: m/z 264.0508; Enantiomeric excess was determined by HPLC with a Chiralcel OJ H column (85 : 15 hexane : 2 propanol, 0.7 ml/min, 254 nm); minor 24.8 enantiomer t r = 21.4 min, major enantiomer t r = 15.4 min; 97% ee; [α] D = -145.7 (c = 0.25, MeOH, 95/5 dr, 97% ee); IR (neat) 3734, 3649, 3374, 3083, 2879, 1574, 1472, 1425, 1105, 754, 722, 700 cm -1 (2S,3R,4R) 3 amino 2 (4 aminophenyl)thiochroman 4 ol (7l) According to the general procedure B, the title compound was obtained by silica gel column chromatography (AcOEt to CHCl 3 : MeOH = 5:1) as a yellow solid. 1 H NMR (400 MHz, DMSO d 6 ) δ 7.30 7.28 (m, 1H), 7.16 (dt, 1H, J = 7.8, 1.6 Hz), 7.08 7.02 (m, 4H), 6.55 (d, 2H, J = 8.6 Hz), 5.13 (br, 2H), 4.55 (d, 1H, J = 2.5 Hz), 4.26 (d, 1H, J = 10.4 Hz), 3.50 (br, 1H), 3.42 (br, 2H), 3.19 (dd, 1H, J = 10.2, 2.5 Hz); 13 C NMR (100 MHz, DMSO d 6 ) δ 148.4, 136.1, 134.0, 131.3, 129.7, 128.0, 124.6, 124.3, 123.7, 114.0, 69.7, 55.1, 45.6; HRMS calcd for C 15 H 17 N 2 OS [M+H] + :273.1056, found: m/z 273.1056; Enantiomeric excess was determined by HPLC with a Chiralcel OD H column (70 : 30 hexane : 2 propanol, 0.7 ml/min, 25.7 254 nm); minor enantiomer t r = 43.2 min, major enantiomer t r = 18.4 min; 92% ee; [α] D = -156.1 (c = 0.125, MeOH, 92% ee); IR (neat) 3734, 3649, 2919, 1619, 1516, 1474, 1289, 1270, 1010, 759, 728 cm -1 S23

(2S,3R,4R) 3 amino 2 (3 aminophenyl)thiochroman 4 ol (7m) According to the general procedure B, the title compound was obtained by silica gel column chromatography (AcOEt to CHCl 3 : MeOH = 5:1) as a yellow solid. 1 H NMR (400 MHz, CDCl 3 ) δ 7.38(d, 1H, J = 7.4 Hz), 7.22 7.08 (m, 4H), 6.82 (d, 1H, J = 7.9 Hz), 6.77 6.75 (m, 1H), 6.65 6.63 (m, 1H), 4.73 (d, 1H, J = 2.7 Hz), 4.36 (d, 1H, J = 10.1 Hz), 3.51 (dd, 1H, J = 9.9, 2.7 Hz), 3.34 (br) 2.03 (br); 13 C NMR (100 MHz, CDCl 3 ) δ 147.0, 138.6, 134.0, 133.6, 131.4, 130.0, 128.6, 125.2, 124.5, 119.0, 115.4, 115.1, 69.5, 55.4, 45.9; HRMS calcd for C 15 H 17 N 2 OS [M+H] + :273.1056, found: m/z 273.1053; Enantiomeric excess was determined by HPLC with a Chiralcel OD H column (70 : 30 hexane : 2 propanol, 0.7 ml/min, 254 nm); minor enantiomer t r = 20.9 min, major enantiomer t r = 20.8 15.7 min; 87% ee; [α] D = -148.2 (c = 0.025, MeOH, 87% ee); IR (neat) 3734, 3649, 3348, 3214, 2923, 1604, 1458, 1297, 1262, 1074, 754, 731, 698 cm -1 (2S,3R,4R) 3 amino 6 (tert butyl) 2 phenylthiochroman 4 ol (7n) According to the general procedure B, the title compound was obtained by silica gel column chromatography ((hexane: AcOEt = 2:1 to CHCl 3 : MeOH = 10:1) as a pale yellow solid. 1 H NMR (400 MHz, CDCl 3 ) δ 7.44 (d, 2H, J = 7.0 Hz), 7.40 7.31 (m, 4H), 7.27 7.24 (m, 1H), 7.07 (d, 1H, J = 8.3 Hz), 4.71 (d, 1H, J = 2.0 Hz), 4.44 (d, 1H, J = 9.9 Hz), 3.53 (d, 1H, J = 9.0 Hz), 2.30 (br, 3H), 1.31 (s, 9H); 13 C NMR (100 MHz, CDCl 3 ) δ 147.6, 138.0, 133.6, 130.2, 129.03, 128.96, 128.3, 128.1, 126.1, 124.9, 70.3, 55.6, 46.4, 34.3, 31.2; HRMS calcd for C 19 H 24 NOS [M+H] + :314.1573, found: m/z 314.1563; Enantiomeric excess was determined by HPLC with a Chiralpak AS H column (95 : 5 hexane : 2 propanol, 0.7 ml/min, 254 nm); minor enantiomer t r = 23.1 min, major enantiomer t r = 18.5 min; 25.8 92% ee; [α] D = -130.2 (c = 0.5, MeOH, 92% ee); IR (neat) 3734, 3649, 3289, 2960, 2901, 1576, 1484, 1455, 1013, 819, 741, 698 cm -1 S24

(2S,3R,4R) 3 amino 6 chloro 2 phenylthiochroman 4 ol (7o) According to the general procedure B, the title compound was obtained by silica gel column chromatography ((hexane: AcOEt = 2:1 to CHCl 3 : MeOH = 5:1) as an orange amorphous. 1 H NMR (500 MHz, CDCl 3 ) δ 7.43 7.42 (m, 3H), 7.39 7.37 (m, 2H), 7.35 7.32 (m, 1H), 7.18 (dd, 1H, J = 8.6, 2.3 Hz), 7.09 (d, 1H, J = 8.3 Hz), 4.63 (d, 1H, J = 2.6 Hz), 4.40 (d, 1H, J = 9.5 Hz), 3.56 3.54 (m, 1H), 2.18 (br, 3H); 13 C NMR (125 MHz, CDCl 3 ) δ 137.7, 135.9, 132.1, 130.7, 130.0, 129.1, 128.9, 128.6, 128.4, 126.6, 69.2, 55.3, 47.1; HRMS calcd for C 15 H 14 NOSCl [M+H] + : 292.0557, found: m/z 292.0556; Enantiomeric excess was determined by HPLC with a Chiralcel OD H column (80 : 20 hexane : 2 propanol, 0.7 ml/min, 25.9 254 nm); minor enantiomer t r = 9.0 min, major enantiomer t r = 7.9 min; 84% ee; [α] D = -110.4 (c = 0.25, MeOH, 90/10 dr, 84% ee); IR (neat) 3734, 3649, 3287, 2902, 1455, 1101, 1024, 810, 736, 698 cm -1 S25

9. 1 H NMR and 13 C NMR spectra of (2S,3R,4R)-3-nitro-2-arylthiochroman-4-ols (6) S26

S27

S28

S29

S30

S31

S32

S33

S34

S35

S36

S37

S38

S39

S40

S41

10. 1 H NMR and 13 C NMR spectra of (2S,3R,4R)-3-amino-2-arylthiochroman-4-ols (7) S42

S43

S44

S45

S46

S47

S48

S49

S50

S51

S52

S53

S54

S55

S56